A randomized single center study comparing hyaluronic acid to vaginal estrogen for treatment of genitourinary syndrome of menopause

Brief description of study

The purpose of this research study is to compare the effectiveness of vaginal hyaluronic acid (HLA) to vaginal estrogen cream for the treatment of genitourinary syndrome of menopause (GSM). GSM is also known as vulvovaginal atrophy, urogenital atrophy, or atrophic vaginitis. It is a condition characterized by changes to the vaginal, vulvar, and urethral areas of post-menopausal women due to a low estrogen state.. Symptoms that result from these changes include vaginal dryness, burning, painful sexual intercourse, increased urinary frequency/urgency, and/or recurrent urinary tract infections. While vaginal estrogen cream has been the gold standard treatment for this condition for many years, not every women is able to use this medication, many wish to avoid hormonal therapy, and some women do not experience significant or any improvement from this treatment. Thus, the goal of this study is to study an alternative, non-hormonal medication, HLA.


Clinical Study Identifier: s19-01922
ClinicalTrials.gov Identifier: NCT04544475
Principal Investigator: Lila Nachtigall.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.